Advancing CAR T-Cell Therapy

2025/12/08 by Upendra Mahat, Asha Das, Vijay Kumar +1 · 1 voice
Engineering · Medicine · #Biomedical Ethics and Regulation #Biomedical and Engineering Education #CAR-T cell therapy research

paper · doi:10.1001/jama.2025.21721

openalex created_date 2025/12/08 · openalex publication_date 2025/12/08 · openalex updated_date 2026/07/28

Abstract

This Viewpoint discusses the recent decision by the US Food and Drug Administration to eliminate Risk Evaluation and Mitigation Strategies requirements for chimeric antigen receptor (CAR) T-cell therapies for the treatment of cancer.

Discussions

• Just gonna drop this here doi.org/10.1001/jama... [bsky, 6 points, 0 comments]

Related

• Safe CAR-T: shedding light on CAR-related T-cell malignancies
• CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
• CAR-T cell manufacturing: Major process parameters and next-generation strategies
• Barriers and Strategies to Enhance CAR ‐T Cell Infiltration in Solid Tumours: A Systematic Review
• CAR-T cell therapy: A new dawn in the treatment of autoimmune disease